Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
1. A method for inhibiting human TNFα activity in a human subject suffering from rheumatoid arthritis comprising administering to the human subject an interleukin-17 inhibitor and an isolated human anti-TNFα antibody, or an antigen binding portion thereof, such that human TNFα activity in the human subject is inhibited, wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a K d of 1×10 −8 M or less and a K off rate constant of 1×10 −3 s −1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −7 M or less.
2. The method of claim 1 , wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a K off rate constant of 5×10 −4 s −1 or less.
3. The method of claim 1 , wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a K off rate constant of 1×10 −4 s −1 or less.
4. The method of claim 1 , wherein the anti-TNFα antibody, or antigen binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −8 M or less.
5. The method of claim 1 , wherein the anti-TNFα antibody, or antigen binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −9 M or less.
6. The method of claim 1 , wherein the anti-TNFα antibody, or antigen binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −10 M or less.
7. The method of claim 1 , wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; and comprises a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.
8. The method of claim 7 , wherein the anti-TNFα antibody, or antigen binding portion thereof, further comprises a light chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5 and a heavy chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6.
9. The method of claim 8 , wherein the anti-TNFα antibody, or antigen binding portion thereof, further comprises a light chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7 and a heavy chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.
10. The method of claim 1 , wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.
11. The method of claim 10 , wherein the anti-TNFα antibody, or antigen binding portion thereof, has an IgG1 heavy chain constant region.
12. The method of claim 10 , wherein the anti-TNFα antibody, or antigen binding portion thereof, has an IgG4 heavy chain constant region.
13. A method for treating rheumatoid arthritis in a human subject comprising administering to the human subject an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, and an interleukin-17 inhibitor, such that the rheumatoid arthritis is treated, wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a K d of 1×10 −8 M or less and a K off rate constant of 1×10 −3 s −1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −7 M or less.
14. The method of claim 13 , wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a K off rate constant of 5×10 −4 s −1 or less.
15. The method of claim 13 , wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a K off rate constant of 1×10 −4 s −1 or less.
16. The method of claim 13 , wherein the anti-TNFα antibody, or antigen binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −8 M or less.
17. The method of claim 13 , wherein the anti-TNFα antibody, or antigen binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −9 M or less.
18. The method of claim 13 , wherein the anti-TNFα antibody, or antigen binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −10 M or less.
19. The method of claim 13 , wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; and comprises a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.
20. The method of claim 19 , wherein the anti-TNFα antibody, or antigen binding portion thereof, further comprises a light chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5 and a heavy chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6.
21. The method of claim 20 , wherein the anti-TNFα antibody, or antigen binding portion thereof, further comprises a light chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7 and a heavy chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.
22. The method of claim 13 , wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.
23. The method of claim 22 , wherein the anti-TNFα antibody, or antigen binding portion thereof, has an IgG1 heavy chain constant region.
24. The method of claim 22 , wherein the anti-TNFα antibody, or antigen binding portion thereof, has an IgG4 heavy chain constant region.